華興資本(01911.HK):被投企業威高血淨成功於上交所主板掛牌上市
格隆匯5月19日丨華興資本(01911.HK)公佈,集團附屬公司作爲管理人的華興新經濟基金之被投企業山東威高血液淨化製品股份有限公司("威高血淨")成功於上海證券交易所主板掛牌上市,股票代碼603014。
威高血淨是掌握自主核心技術的中國血液淨化行業龍頭。自2004年創立以來,公司不斷投入研發並積累技術經驗,圍繞血液透析和腹膜透析兩大戰略方向,完成了包含透析器、透析機、血液管路、腹膜透析液在內的血液淨化全產業鏈佈局。華興新經濟基金於2022年領投威高血淨上市前融資,總投資金額4.5億人民幣,這充分體現了集團對威高血淨及其行業領先地位的高度認可與堅定信心,也特顯了華興新經濟基金管理團隊的優秀投研能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.